Mirati Therapeutics Inc. buy Ruckelsbuckel
Start price
21.08.22
/
50%
€76.50
Target price
21.08.23
€230.00
Performance (%)
6.54%
End price
04.09.22
€81.50
Summary
This prediction ended on 04.09.22 with a price of €81.50. With a performance of 6.54%, the BUY prediction by Ruckelsbuckel for Mirati Therapeutics Inc. closed with a slight gain. Ruckelsbuckel has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Mirati Therapeutics Inc. | - | - | - |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% |
According to Ruckelsbuckel what are the pros and cons of Mirati Therapeutics Inc. for the foreseeable future?
Pros
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Good rating
Capable Management
ROE higher than 10% per year
Stable Large shareholder and/or long term investor
High dividend yield expected
positive Cash Flow expected
Normal challenges to pay loans and raise capital
Very good company culture
Innovative
Some uniques
Sustainability is important
Top 10 in its market
Known brand
Cons
Probably not worthwhile Investment
Lower EBIT Margin than peer group
High valuation
Little Investments for future growth
High risks for its business
Dependend from some customers or products
High risks in the balance sheet
Growths slower than the competition
Significant cyclical dependencies
Outdated or very high risk business model
Comments by Ruckelsbuckel for this prediction
In the thread Mirati Therapeutics Inc. diskutieren
Buy mit Kursziel 230,0